DiaMedica Inc. (TSX VENTURE: DMA) today announced the appointment
of Dr. Michael Giuffre to the company's Board of Directors.
Dr. Giuffre is a Clinical Professor of Cardiac Sciences and
Pediatrics at the University of Calgary. Dr Giuffre is currently a
member on the board's of the Alberta Medical Association and Unicef
Canada. He is a past representative to the board of the Calgary
Health Region and is an active participant in the biotechnology
business sector.
"Dr. Giuffre's clinical and business experience, particularly
with his extensive cardiovascular background, will add additional
depth to our Board," stated Mr. Rick Pauls, President and CEO of
DiaMedica.
"I am pleased to be joining the Board of Directors of DiaMedica
at such a progressive time in its history," stated Dr. Giuffre.
"DiaMedica has very promising technology and I look forward to
leveraging my experience as the company prepares for exciting and
ambitious milestones."
About Dr. Michael Giuffre
As a Clinical Professor of Cardiac Sciences and Pediatrics at
the University of Calgary, Dr Giuffre maintains a portfolio of
clinical practice, cardiovascular research, and university
teaching. He maintains on-going involvement in both health care
administration, and in the biotechnology business sector. Dr
Giuffre is Past President of the Calgary and Area Physicians
Association (CAPA) and a past representative to the board of the
Calgary Health Region. Dr Giuffre holds a BSc in cellular and
microbial biology, a PhD candidacy in molecular virology, an MD and
an MBA. His Canadian Royal College board certified specialties
include Pediatrics, Pediatric Cardiology and a subspecialty in
Pediatric Electrophysiology.
As a biotechnology consultant, Dr. Giuffre has been involved
with RedSky Inc. (acquired by Research in Motion), MDMI, and
MedMira Inc. He is currently on the boards of IC2E Inc and FoodChek
Inc. He serves on the Medical Advisory Board of the SADS Foundation
and on the boards of Unicef Canada and the Alberta Medical
Association. He is also an MD-MP contact for the Canadian Medical
Association.
Dr Giuffre has recently received a Certified and Registered
Appointment by the American Academy of Cardiology, "Distinguished
Fellow of the American Academy of Cardiology," and in 2005 was
awarded "Physician of the Year" by the Calgary Medical Society.
About DiaMedica
DiaMedica is a biopharmaceutical company focused on developing
novel treatments for diabetes and neurological disorders. The
Company's type 2 diabetes program is based on a critical liver
nerve signaling mechanism involved in enhancing insulin sensitivity
after meal consumption. Two of DiaMedica's products, DM-71 and
DM-99, have previously demonstrated human efficacy in lowering
blood sugar levels in people diagnosed with type 2 diabetes based
on this novel nerve signaling mechanism.
DiaMedica has expanded its DM-199 recombinant protein program
into neurological and autoimmune disorders. The Company has
demonstrated that DM-99, the naturally occurring form of DM-199,
confers neural protection (protects brain cells) and triggers
neural stem cell proliferation (creates brain cells) for the
treatment of numerous neurological disorders including Alzheimer's
disease. DiaMedica is listed on the TSX Venture Exchange under the
trading symbol "DMA". For further information please visit
www.diamedica.com.
Caution Regarding Forward-Looking Information
Certain statements contained in this press release constitute
forward-looking information within the meaning of applicable
Canadian provincial securities legislation (collectively, the
"forward-looking statements"). These forward-looking statements
relate to, among other things, DiaMedica's objectives, goals,
targets, strategies, intentions, plans, beliefs, estimates and
outlook, and can, in some cases, be identified by the use of words
such as "believe," "anticipate," "expect," "intend," "plan,"
"will," "may" and other similar expressions. In addition, any
statements that refer to expectations, projections or other
characterizations of future events or circumstances are
forward-looking statements. Specifically, this press release
contains forward-looking statements regarding matters such as, but
not limited to, the prospective Offering and the proceeds from the
Offering, the anticipated use of proceeds from the Offering,
regulatory approval of the Offering, and our other plans, estimates
and expectations, including the completion of our proposed
acquisition of Sanomune Inc. These statements reflect management's
current beliefs and are based on information currently available to
management. Certain material factors or assumptions are applied in
making forward-looking statements, and actual results may differ
materially from those expressed or implied in such statements.
Important factors that could cause actual results to differ
materially from these expectations include, among other things:
uncertainties and risks related to our ability to complete the
Offering, the availability of financing, risks and uncertainties
relating to the anticipated use of proceeds, changes in debt and
equity markets, uncertainties related to clinical trials and
product development, rapid technological change, uncertainties
related to forecasts, competition, potential product liability,
additional financing requirements and access to capital, unproven
markets, the cost and supply of raw materials, management of
growth, effects of insurers' willingness to pay for products, risks
related to regulatory matters and risks related to intellectual
property matters.
Additional information about these factors and about the
material factors or assumptions underlying such forward-looking
statements may be found in the body of this news release, as well
as under the heading "Risk Factors" contained in DiaMedica's 2008
annual information form. DiaMedica cautions that the foregoing list
of important factors that may affect future results is not
exhaustive. When relying on DiaMedica's forward-looking statements
to make decisions with respect to DiaMedica, investors and others
should carefully consider the foregoing factors and other
uncertainties and potential events. Such forward-looking statements
are based on a number of estimates and assumptions which may prove
to be incorrect, including, but not limited to, assumptions
regarding the availability of financing for research and
development companies, general business and economic conditions,
and DiaMedica's ability to complete its proposed acquisition of
Sanomune Inc. These risks and uncertainties should be considered
carefully and investors and others should not place undue reliance
on the forward-looking statements. Although the forward-looking
statements contained in this press release are based upon what
management believes to be reasonable assumptions, DiaMedica cannot
provide assurance that actual results will be consistent with these
forward-looking statements. DiaMedica undertakes no obligation to
update or revise any forward-looking statement. Additional risk
factors, factors which could cause actual results to differ
materially from expectations, and assumptions relating specifically
to our proposed acquisition of Sanomune Inc. may be found in our
press release dated February 18, 2010.
The TSX Venture Exchange does not accept responsibility for the
adequacy or accuracy of this release.
Contacts: DiaMedica Inc. Kevin Richardson, Ph.D 204.478.5605
204.453.3745 (FAX) krichardson@diamedica.com
DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jun 2024 to Jul 2024
DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jul 2023 to Jul 2024